AMD

4
Pipeline Programs
4
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
1
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
2 programs
1
1
Anecortave Acetate Sterile Suspension, 30 mg/mLPhase 31 trial
anecortave acetatePhase 21 trial
Active Trials
NCT00346866Completed136Est. Dec 2001
NCT00332657TerminatedEst. Dec 2008
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ABBV-RGX-314Phase 2/31 trial
Active Trials
NCT04704921Recruiting630Est. Nov 2027
LP
Lee's PharmaceuticalChina - Guangzhou
1 program
1
TAB014Phase 11 trial
Active Trials
NCT03675880Unknown24Est. Apr 2019
NV
Notal VisionVA - Manassas
2 programs
NOTAL OCT V2.5N/A1 trial
NOTAL-OCT V3.0N/A1 trial
Active Trials
NCT03600519CompletedEst. Jan 2020
NCT04078672CompletedEst. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AlconAnecortave Acetate Sterile Suspension, 30 mg/mL
AbbVieABBV-RGX-314
Alconanecortave acetate
Lee's PharmaceuticalTAB014
Notal VisionNOTAL-OCT V3.0
Notal VisionNOTAL OCT V2.5

Clinical Trials (6)

Total enrollment: 790 patients across 6 trials

NCT00332657AlconAnecortave Acetate Sterile Suspension, 30 mg/mL

Anecortave Acetate Risk Reduction Trial (AART)

Start: Sep 2006Est. completion: Dec 2008
Phase 3Terminated
NCT04704921AbbVieABBV-RGX-314

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

Start: Dec 2020Est. completion: Nov 2027630 patients
Phase 2/3Recruiting
NCT00346866Alconanecortave acetate

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

Start: May 2000Est. completion: Dec 2001136 patients
Phase 2Completed
NCT03675880Lee's PharmaceuticalTAB014

TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects

Start: Jun 2018Est. completion: Apr 201924 patients
Phase 1Unknown
NCT04078672Notal VisionNOTAL-OCT V3.0

Retinal Imaging Using NOTAL-OCT V3.0

Start: Dec 2019Est. completion: Mar 2023
N/ACompleted
NCT03600519Notal VisionNOTAL OCT V2.5

Retinal Imaging Using NOTAL-OCT V2.5

Start: Jul 2018Est. completion: Jan 2020
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 790 patients
4 companies competing in this space